SA
Log In
SNDX
OverviewIntelligenceChart
Next earnings: Aug 3, 2026 · After close
Signal
Leaning Bearish1↓
Price
1→
Move→+0.70%Quiet session
Volume
1→
Volume→0.7× avgNormal activity
Technical
1↓
RSI↓RSI 38Momentum negative
PRICE
Prev Close
19.96
Open
20.02
Day Range19.45 – 20.15
19.45
20.15
52W Range8.58 – 25.59
8.58
25.59
68% of range
VOLUME & SIZE
Avg Volume
2.2M
FUNDAMENTALS
P/E Ratio
-7.2x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.94
Market-like
Performance
1D
+0.70%
5D
-3.92%
1M↓
-17.25%
3M
-0.25%
6M
+33.11%
YTD
-4.33%
1Y↑
+48.12%
Best: 1Y (+48.12%)Worst: 1M (-17.25%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +397% YoY · 98% gross margin
Valuation
FAIR
P/E not available
Health
WEAK
CR 5.5 · FCF negative
Lean Bullish
Key MetricsTTM
Market Cap$1.77B
Revenue TTM$217.17M
Net Income TTM-$243.25M
Free Cash Flow-$278.35M
Gross Margin98.0%
Net Margin-112.0%
Operating Margin-102.9%
Return on Equity-256.7%
Return on Assets-51.5%
Debt / Equity8.30
Current Ratio5.47
EPS TTM$-2.81
Alpha SignalsView Intelligence →

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
2 strong4 concern
31/100
Liquidity
5.47Strong
Leverage
8.30Concern
Coverage
-2.8xConcern
ROE
-256.7%Concern
ROIC
-57.8%Concern
Cash
$135MStrong
ANALYST COVERAGE21 analysts
BUY
▲ +106.5%upside to target
L $37.00
Med $41.50consensus
H $46.00
Buy
2095%
Hold
15%
20 Buy (95%)1 Hold (5%)0 Sell (0%)
Full report →
Stock Health
Composite Score
4 of 5 signals bullish
8/10
Technicals
●
RSI RangeRSI 38 — Bearish momentum
✗
Volume
●
Volume FlowLean Accumulation
✓
Fundamentals
●
Last EarningsBeat estimates
✓
●
Analyst ConsensusBuy
✓
●
LiquidityCurrent Ratio 5.47 — healthy liquidity
✓
Upcoming Events
EEarnings Report · After CloseMay 7, 2026
Tomorrow
DEx-Dividend DateAug 4, 2026
In 90 days
PDividend PaymentAug 6, 2026
In 92 days
Research
Fundamentals→Financials→Analysts→Earnings→Growth→Key Metrics→Technical Analysis→Intelligence→
Technicals
Technical SetupBULLISH
Technicals →

Trend

▲ UptrendGolden Cross · 50D leads 200D by 37.0%

+14.7% vs SMA 50 · +57.2% vs SMA 200

Momentum

RSI37.7
Momentum fading
MACD+0.76
Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$25.59+27.3%
Current
$20.10
EMA 50
$18.28-9.0%
EMA 200
$12.79-36.4%
52W Low
$8.58-57.3%
52-Week RangeMid-range
$8.5868th %ile$25.59
Squeeze SetupVolume-based
Moderate Squeeze Setup

Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.

20-Day Money Flow
Acc days:4
Dist days:1
Edge:+3 acc
Volume Context
Avg Vol (50D)2.1M
Recent Vol (5D)
1.7M-16%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 9 analysts
Full estimates →
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$168.1M
$163.0M–$173.9M
—-$3.10—
±6%
High9
FY2026(current)
$348.1M
$322.9M–$399.9M
▲ +107.0%-$1.77—
±50%
High9
FY2027
$513.2M
$447.7M–$652.5M
▲ +47.4%-$0.54—
±50%
High9
Range confidence:Tight (high)ModerateWide (low)
Earnings HistorySNDX
Last 8Q
+4.6%avg beat
Beat 6 of 8 quartersMissed 2↑ Estimates rising
+12%
Q3'24
+13%
Q4'24
-2%
Q1'25
+6%
Q2'25
+17%
Q3'25
+5%
Q4'25
-34%
Q1'26
+19%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Metzger Michael ACEO
$361K
Feb 9
SELL
Goldan Keith A.CFO
$72K
Feb 9
SELL
Metzger Michael ACEO
$153K
Feb 6
SELL
Goldan Keith A.CFO
$43K
Feb 6
SELL
Metzger Michael ACEO
$2.6M
Sep 8
SELL
Podlesak DennisDir
$304K
Aug 18
SELL
Financials

INSTITUTIONAL OWNERSHIP

13-F Filings →
1
Nuveen, LLC
1.5M▲
2
Candriam S.C.A.
925K—
3
abrdn plc
287K▼
4
TORRAY INVESTMENT PARTNERS LLC
105K▲
5
Yelin Lapidot Holdings Management Ltd.
96K▼
6
TEMA ETFS LLC
58K▼
7
PROFUND ADVISORS LLC
56K▼
8
ENVESTNET ASSET MANAGEMENT INC
42K▲
News & Activity

SNDX News

20 articles · 4h ago

About

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.

Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Briggs Morrison
Website
syndax.com ↗
Keith Alan GoldanCFO, Treasurer & Principal Accounting Officer
Luke J. AlbrechtSenior Vice President, General Counsel & Secretary
Sharon KlahreVice President of Investor Relations & Communications
Peers— Health Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt Cap↓P/ERev GrwMarginELO
SNDX◀
$20.10+0.70%$1.8B—+62783.8%-16560.4%1500
BBIO
$68.78-0.30%$13.3B—+12626.1%-14525.8%1500
GH
$89.52-1.81%$11.7B—+3288.2%-4239.0%1500
MDGL
$502.47-3.12%$11.5B—+43205.3%-3008.0%1500
AXSM
$223.06-0.29%$11.4B—+6554.5%-2868.8%1500
ARWR
$74.93-1.91%$10.5B51.9+2325815.3%-19.7%1500
ENSG
$175.95-3.34%$10.3B28.0+1871.5%680.1%1500
Sector avg—-1.44%—39.9+350877.8%-5791.6%1500

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance